二盐酸珠氯噻醇 | 633-59-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻喃类
• 中文名称: 二盐酸珠氯噻醇
• 中文别名: 氯哌噻吨二盐酸盐；高抗素；珠氯噻醇盐酸盐
• 英文名称: 2-[4-[3-(2-Chlorothioxanthen-9-ylidene)propyl]piperazine-1,4-diium-1-yl]ethanol;dichloride
• 英文别名: 2-[4-[3-(2-chlorothioxanthen-9-ylidene)propyl]piperazine-1,4-diium-1-yl]ethanol;dichloride
• CAS: 633-59-0
• 化学式: C22H27Cl3N2OS
• 分子量: 473.9
• InChiKey: LPWNZMIBFHMYMX-UHFFFAOYSA-N

物化性质

• 熔点：
  250-260° (dec)
• 溶解度：
  极易溶于水；微溶于乙醇(96%)；极微溶于乙醚。

计算性质

• 辛醇/水分配系数(LogP)：
  5.08
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  52
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
  申请人：Northwestern University

  公开号：US10098893B2

  公开（公告）日：2018-10-16

  Disclosed are methods and kits for diagnosing, prognosing, and treating patients having psychiatric disorders. The methods may include assessing whether a patient has a treatment resistant psychiatric disorder or assessing whether the patient is likely to develop a treatment resistant psychiatric disorder. The methods may include detecting genetic markers such as the single nucleotide polymorphism (SNP) in genes present in a genomic nucleic acid sample from the patient, and/or receiving, as a caregiver, the results of tests indicating whether the genetic markers are present in the genomic nucleic acid sample from the patient. The methods may include administering treatment to the patient, for example, based on the detected genetic markers, and administering treatment may include administering new antipsychotic drugs (APDs) that are trace amine-associated receptor 1 (TAAR1) agonists.

  所公开的是用于诊断、预后和治疗精神障碍患者的方法和试剂盒。这些方法可包括评估患者是否患有抗药性精神障碍，或评估患者是否有可能患上抗药性精神障碍。这些方法可包括检测患者基因组核酸样本中存在的遗传标记，如基因中的单核苷酸多态性（SNP），和/或作为护理者接收表明患者基因组核酸样本中是否存在遗传标记的检测结果。这些方法可包括对患者进行治疗，例如，根据检测到的遗传标记进行治疗，治疗可包括使用新的抗精神病药物（APDs），这些药物是痕量胺相关受体 1（TAAR1）激动剂。
• Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
  申请人：ELCELYX THERAPEUTICS, INC.

  公开号：US10159658B2

  公开（公告）日：2018-12-25

  Compositions and methods comprising at least one biguanide compound and at least one statin combined with at least one additional active agent in fixed dose combinations are provided for reducing cardiometabolic risk, and for the treatment of cardiovascular disease, wherein the biguanide compound is formulated for delayed release.

  本发明提供了包含至少一种双胍类化合物和至少一种他汀类药物以及至少一种额外活性剂的组合物和方法，其固定剂量组合物用于降低心脏代谢风险和治疗心血管疾病，其中双胍类化合物配制成缓释剂。
• Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
  申请人：The Scripps Research Institute

  公开号：US10660899B2

  公开（公告）日：2020-05-26

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

  本发明提供了用神经递质受体调节剂诱导少突胶质祖细胞向成熟髓鞘细胞命运分化的方法。本发明还提供了通过施用所述神经递质受体调节剂刺激有需要的受试者增加髓鞘化的方法。本发明还提供了使用神经递质受体调节剂治疗脱髓鞘疾病的方法。
• Methods, kits, and devices utilizing HTR2C polymorphisms for diagnosing, prognosing, and treating psychiatric disorders in a patient
  申请人：Northwestern University

  公开号：US11174514B2

  公开（公告）日：2021-11-16

  Disclosed are methods, kits, and devices for diagnosing and treating psychiatric, disorders and the symptoms thereof. The methods, kits, and devices relate to identifying genetic markers that may be utilized to diagnose and/or prognose a patient and treat the diagnosed and/or prognosed patient by administering a drug the patient based on the genetic marker having been identified. Genetic markers identified in the methods may include HTR2C polymorphisms such as a polymorphism resulting in a Cys23Ser amino acid substitution, an rs3813929 (−759C/T) polymorphism, and an rs518147 (−697G/C) polymorphism).

  所公开的是用于诊断和治疗精神病、失调症及其症状的方法、试剂盒和设备。这些方法、试剂盒和设备涉及鉴定遗传标记，可用于诊断和/或预后患者，并根据已鉴定的遗传标记给患者用药，从而治疗已诊断和/或预后的患者。方法中鉴定的遗传标记可包括 HTR2C 多态性，如导致 Cys23Ser 氨基酸置换的多态性、rs3813929 (-759C/T) 多态性和 rs518147 (-697G/C) 多态性）。
• PHARMAZEUTISCHE DARREICHUNGSFORM
  申请人：Müller, Dieter

  公开号：EP0907388A1

  公开（公告）日：1999-04-14